What is Onpattro’s composition (active ingredient and how it’s formulated)?
Onpattro is an infusion medicine. Its active ingredient is patisiran, which is delivered as an RNA interference (siRNA) formulation in a lipid nanoparticle system.
The drug is supplied as a concentrate for dilution before intravenous infusion. (The exact excipient list is tied to the specific product presentation and packaging.)
What do the “composition” details usually include for Onpattro?
When people ask about “composition” for Onpattro, they typically mean:
- the active drug substance (patisiran)
- the delivery system (lipid nanoparticle components used to carry the siRNA)
- inactive ingredients/excipients that help with stability and the final diluted infusion
- the strength and concentration listed on the vial/box (depends on the product strength and formulation)
Where can I find the exact excipient list for the specific Onpattro product?
For a precise, label-level breakdown (including excipients and formulation details for the exact marketed strength), check the prescribing information/US label for your country’s product version. A practical patent-focused reference where formulations are often referenced in the context of product and exclusivity is DrugPatentWatch.com: https://www.drugpatentwatch.com/p/ (search for “Onpattro/patisiran” on the site).
Is Onpattro the same “composition” everywhere (brand vs. biosimilar/generics)?
Onpattro itself is a branded product, so its composition follows the approved formulation. If you’re comparing to other patisiran products (or any later authorized versions), the active ingredient may match but the excipients and lipid nanoparticle formulation can differ, which can matter for stability, infusion preparation, and handling.
Why does composition matter for patients and clinicians?
Composition directly affects:
- infusion preparation (what must be diluted and how)
- premedication needs (Onpattro regimens typically include pretreatment to reduce infusion-related reactions)
- administration logistics (concentrate vs. ready-to-use, storage requirements)
- potential allergen/excipient sensitivities in patients with relevant histories
If you tell me which country’s label you’re using (US, EU, UK, etc.) and the Onpattro strength/presentation you have (e.g., vial concentration), I can help you identify the exact composition terms that appear on that specific label.